In stock · depth page
Retatrutide — recent literature 2024–2026 (RUO)
Triple GIP / GLP-1 / glucagon receptor agonist · LY3437943
Retatrutide 10 / 20 / 30 mg · literature note
For laboratory research use only. Not for human or veterinary use, consumption, compounding into a medicine, or injection. Not authorized by Health Canada. Literature on this page is scientific context only. This page is not a licensed drug, a wellness protocol, or a dosing guide.
PubMed-verified recent literature for Canadian laboratory procurement of retatrutide (LY3437943). Clinical and metabolic-outcome papers are cited for identity of the published research compound. They are not wellness or human-use claims.
How to read this set
The locked core (Coskun 2022, Jastreboff 2023, Rosenstock 2023) stays on the parent brief and is repeated here so the recent set has its identity anchors. The 2024–2026 rows are pathway, metabolic-research, and analytical-detection papers. Frame them as literature, not use instructions.
Mao et al. (Organic Letters, 2026) is a synthesis footnote for laboratories that ask whether peer-reviewed synthetic coverage exists beyond trial reports. It does not replace the lot COA.
Identity
Form
Lyophilized powder, sealed vial
Strength
10 mg, 20 mg, 30 mg lyophilized vials
Purity
≥99% HPLC (see the lot COA)
CAS
- Retatrutide: 2381089-83-2
PubMed
Selected literature
- PMID 35985340 (2022) Coskun et al., Cell Metabolism — LY3437943 discovery / proof of concept (triple glucagon, GIP, GLP-1)
- PMID 37366315 (2023) Jastreboff et al., NEJM — Phase 2 triple-hormone-receptor agonist metabolic research
- PMID 37385280 (2023) Rosenstock et al., Lancet — Phase 2 triple-agonist study in type 2 diabetes research settings
Recent literature (2023–2026)
- PMID 38858523 (2024) Sanyal et al., Nature Medicine — Phase 2a MASLD / metabolic-liver research trial
- PMID 42250575 (2026) Bajaj et al., Lancet — GIP / GLP-1 / glucagon receptor agonist research publication in type 2 diabetes settings
- PMID 42745421 (2026) Carneiro et al., Rapid Communications in Mass Spectrometry — LC-HRMS detection / excretion profile of retatrutide (analytical context)
- PMID 42224238 (2026) Mao et al., Organic Letters — hydrophobic tag–assisted liquid-phase synthesis of retatrutide (chemistry context)
Literature is scientific context only. A paper does not make a research vial into a licensed medicine.
Bench reconstitution
Reconstitute on the parent brief: bacteriostatic water to the mg/mL the protocol specifies, solvent down the wall, swirl, do not vortex. Record the concentration. This page does not add a second method.
Diluent page: bacteriostatic water.
Storage
Keep the lyophilized vial at 2–8 °C, protected from light and moisture, until the bench protocol calls for it. After reconstitution, hold at 2–8 °C; use within the sterility window your laboratory controls allow. Do not freeze–thaw repeatedly. Record open date and concentration in the notebook. Confirm the lot COA before you adopt a hold time.
Certificate of analysis
Every product has a View COA button. Where the lot certificate of analysis (identity and HPLC purity) is posted, it opens the certificate with a PDF download. Where it is not posted yet, the same button sends a request by email to request@pharmapeptidesrx.com, or you can write that address with the SKU. This page is not a COA. Ask for the lot-matched COA with the research request.
Lab FAQ
Will you invent additional PMIDs if a buyer asks for more 2026 papers?
No. Only PubMed-verified IDs are listed. A requested paper is added only after it is checked against NCBI. Write request@pharmapeptidesrx.com. This page does not publish prices or banking details. Invoices go out from request@ only.
In this library
In stock · list price
Request from the catalog
Every vial on the catalog shows its CAD list price. Add it to your request and we email the invoice. Labs pay by Interac e-Transfer. No card checkout.